CBAY

CymaBay Therapeutics, Inc. · NASDAQ

Performance

+0.19%

1W

+37.09%

1M

+68.48%

3M

+134.4%

6M

+36.45%

YTD

+294.01%

1Y

Profile

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Investment Analysis Report: CBAY

Overview

In this investment analysis report, we will delve into the financial statements of CBAY, a company operating in the Health Technology sector within the Biotechnology industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating cash flow...

See more ...

Technical Analysis of CBAY 2024-02-23

Overview:

In analyzing the technical indicators for CBAY over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key factors, we aim to offer valuable insights and predictions for the upcoming days.

Trend Analysis:

...
See more ...

Recent News & Updates